Direct tumor targeting using nanobioconjugate with a combination of monoclonal antibodies for breast cancer treatment.

@article{Inoue2009DirectTT,
  title={Direct tumor targeting using nanobioconjugate with a combination of monoclonal antibodies for breast cancer treatment.},
  author={S. Inoue and H. Golseiz and R. Patil and Hui Ding and S. Rudenkyy and E. Holler and K. Black and J. Ljubimova},
  journal={Cancer Research},
  year={2009},
  volume={69},
  pages={2124}
}
CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts Abstract #2124 Objective: Nanobioconjugate engineered based on polymalic acid (PLMA), which is derived from slime mold that is non-toxic, non-immunogenic, and biodegradable. Using combination of targeting antibodies, the nanopolymer candidates for drug delivery can efficiently reach breast cancer without affecting normal tissue in vivo. Controllable, unique drug releases tumor inhibiting agents specifically into cancer cells… Expand